Cramer said the drug store chain is poised to double its footprint with the acquisitions of the Eckard and Brooks units of Montreal's Jean Coutu. And while investors are wringing their hands over
push to cut prices on some generic drugs, "Rite Aid is absolutely bucking this whole trend," Cramer said.
Cramer also likes
, saying CEO Howard Schultz is leading a solid global expansion. Cramer was won over by the recent nickel-a-cup price increase, which he says will bolster margins. He expects the stock to go to 40 from a recent 38 and stay there for a bit, since 40 "would be eight straight points up."
At the time of publication, Cramer had no position in stocks mentioned.
Jim Cramer is a director and co-founder of TheStreet.com. He contributes daily market commentary for TheStreet.com's sites and serves as an adviser to the company's CEO. Outside contributing columnists for TheStreet.com and RealMoney.com, including Cramer, may, from time to time, write about stocks in which they have a position. In such cases, appropriate disclosure is made. To see his personal portfolio and find out what trades Cramer will make before he makes them, sign up for
Action Alerts PLUS. Listen to Cramer's RealMoney Radio show on your computer; just click
here. Watch Cramer on "Mad Money" at 6 p.m. ET weeknights on CNBC. Click
here to order Cramer's latest book, "Real Money: Sane Investing in an Insane World," click
here to get his second book, "You Got Screwed!" and click
here to order Cramer's autobiography, "Confessions of a Street Addict." While he cannot provide personalized investment advice or recommendations, he invites you to send comments on his column by
TheStreet.com has a revenue-sharing relationship with Traders' Library under which it receives a portion of the revenue from Traders' Library purchases by customers directed there from TheStreet.com.